Intuitive Surgical (ISRG) is expected to report its third-quarter earnings results on October 18. In this series, we’ll be taking a look at the company’s expected top line, operational, and bottom line performances in the quarter. We’ll also look back on its performance so far this year.
The company develops and commercializes da Vinci surgical systems and related instruments, which combine the benefits of minimally invasive surgery with the precision of open surgery.
Intuitive’s products in different categories include the da Vinci surgical systems, InSite, and the Firefly Fluorescence imaging systems. Its instruments and accessories include EndoWrist, EndoWrist Vessel Sealer, EndoWrist Stapler, and training technologies.
In September, Intuitive submitted a premarket notification to the FDA for its flexible robotic-assisted and catheter-based platform. This platform is designed to navigate through small lung airways and reach peripheral nodules for biopsies.
Top line forecast
Analysts expect Intuitive Surgical’s revenue to rise 13.35% from $806.1 million in the third quarter of 2017 to $913.7 million in the third quarter of 2018. In the third quarter of 2017, the company’s revenue rose 18.04%. Over the last four quarters, Intuitive Surgical’s revenue growth has ranged from 17.9% to 25.7%.
For 2018 and 2019, Intuitive is expected to generate revenues of $3.7 billion and $4.2 billion, respectively. In 2017, it generated revenue of $3.13 billion.
We’ll take a look at Intuitive Surgical’s expected bottom line numbers for the third quarter in the next article.